Key Takeaways

  • The FDA initially sent WHOOP a warning letter to halt wrist-based blood pressure tracking, arguing that blood pressure metrics require medical clearance.
  • WHOOP fought the classification by mobilizing 70,000 members into a voluntary stress, sleep, and blood pressure clinical study to gather proof.
  • The pushback forced the FDA to update its official guidelines, carving out non-diagnostic blood pressure monitoring as consumer wellness.
  • WHOOP plays both sides of the regulatory line, keeping lifestyle tracking under wellness while securing 510(k) clearance for medical features like wrist-based ECG.

The Line Between Diagnosis and Tracking

Regulators love clean borders. Silicon Valley loves blurry ones. When WHOOP introduced wrist-based blood pressure monitoring, the Food and Drug Administration saw a medical metric operating without a prescription or clearance. The agency issued a warning letter demanding compliance.

Most founders panic when an agency like the FDA comes knocking. The natural reflex is to pull the feature, hire outside counsel, and spend millions begging for permission. Ahmed took a different route. He drew a hard line between treating an illness and giving people data about their own bodies.

As Ahmed explains, “The FDA is really supposed to evaluate products that have a medical diagnosis. And then if you're not providing a medical diagnosis, then it falls under a category called wellness.”

If a device tells you that you have hypertension, it is diagnosing a disease. That requires clinical validation, physician oversight, and formal 510(k) clearance. But if the band simply tracks baseline physiological trends, telling you how your body responds to a night of bad sleep or a hard workout, it belongs to you. That distinction is the entire economic engine of modern consumer health.

Pushing Back With 70,000 Users

Standing your ground against federal regulators requires receipts. Words alone do not reverse a warning letter. WHOOP turned its user base of four million members into a distributed research lab.

Ahmed opened up enrollment to his community. “One of the ways that we collected a huge data set on it was in a collaboration with our members where we asked members if they wanted to participate in a stress, sleep and blood pressure study,” Ahmed says. “As part of that we actually had 70,000 people enroll.”

Armed with data from 70,000 people, WHOOP made its case directly in the public square. “The FDA came back and said that they felt like it needed to be regulated. They actually sent us a warning letter. There was a big disagreement that played out that was quite public about it. But we stuck to our guns.”

The gamble paid off. The agency did not shut down the feature. Instead, it updated its own guidance, formally recognizing that blood pressure tracking can serve a wellness purpose outside diagnostic medicine. “Through a long process, the FDA actually has since updated their guidelines I think based on our case, but also based on feedback from the industry, that supports that blood pressure can also have wellness applications,” Ahmed notes.

WHOOP still pursues formal medical approvals when the feature crosses into diagnosis. “Whoop also has medical clearances from the FDA,” Ahmed says. “Our ECG feature, where you can literally do an ECG from your wrist by just putting your fingers on the Whoop, that's an FDA cleared product 510(k).”

The playbook is not avoiding regulation entirely. It is knowing exactly which category your feature belongs to, and refusing to let an agency push you into a slower lane without a fight.

What to Do With This

Audit your product's customer-facing copy this week. If you collect or display data that overlaps with regulated industries, scrub every claim that promises an outcome or diagnosis. Shift your language to trend observation and baseline habits, building a data moat before an agency defines your product for you.